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ABSTRACT
Radiation or marrow toxic emergencies can lead to severe pancytopenia along with other multiorgan injury.
Experience in managing severe myelosuppression suggests that hematology, oncology and transplantation
physicians should participate in preparedness planning for such events. Evaluation and management of marrow
injured patients requires their expertise. Understanding of the biology of radiation injury, clinical dosimetry to
estimate exposure and defined elements of supportive care are essential for appropriate emergency and
follow-up treatment. Some patients with expected radiation exposure >4Gy may have extended myelosup-
pression and be candidates for consideration of allogeneic hematopoietic stem cell transplantation (HSCT).
Issues related to patient screening, supportive care, and planning for transplantation are best addressed ahead
of time to enable readily available information and guidelines for patient management. National and interna-
tional contingency planning for such urgencies is underway as effective emergency mobilization requires
forethought, education, and pre-established protocols for treatment. Radiation and marrow toxic emergencies
may seem unlikely, but the best approach to appropriate medical support is preparedness, contingency
planning, and planned research to improve guidelines for the future.
© 2007 American Society for Blood and Marrow Transplantation
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MNTRODUCTION
Accidental exposure to myelotoxic radiation or
hemicals in a terrorist, industrial accident, or military
ircumstance is a current and continuing threat. Sud-
en high-dose exposure from a blast or radiation leak
r slow ongoing partial body exposure from a dirty
omb or radiation dispersal device left in a public
lace may produce differing exposure and intensity.
ppropriate management of the hematologic conse-
uences and the injury, trauma, or burns requires
lanning and preparedness for contingencies [1-4].
eyond the ﬁrst response of assessment, stabilization
f trauma, and treatment of burns, evaluation and
anagement of myelosuppression create clinical cir-
umstances most familiar to physicians managing pa- dients with hematologic cancer or HSCT [1,2,5].
ancytopenia and immune suppression are also con-
equences of acute radiation syndrome [6,7]. Appro-
riate contingency planning allows foresight and
reparedness to develop evaluation and treatment
uidelines [8]. Experience from previous radiation ac-
idents has spurred planning in the United States and
n Europe. Some experiences in responding to urgent
ass medical contingencies (eg, hurricanes) can in-
orm plans for management of radiation emergencies.
SCT FOR TREATMENT OF RADIATION-INDUCED
YELOSUPPRESSION
Published experience documents30 patients un-
ergoing HSCT for treatment of irradiation-associ-
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D. Weisdorf et al.104ted marrow toxicity [1,3-5]. Only 4 patients survived
nd all rejected their graft, thus emphasizing the com-
lexities in assessing extent of immune suppression
hich might be distinct from myelosuppression. Iden-
ifying proper and expediently available donors, con-
itioning regimen, GVHD prophylaxis, plus support-
ve care techniques tailored to the irradiated patient are
hallenging. These may differ from the preplanned, de-
ned exposures accompanying conventional HSCT for
reatment of cancer or other life-threatening diseases.
ome published experience has included serial trans-
lantations of grafts from numerous donors because
f graft failure [3,9,10]. This highlights the difﬁculty
n assessing the extent of immunosuppression experi-
nced by patients undergoing intermediate-dose, whole
r partial body irradiation. In general, patients ex-
osed to 4-9 Gy will develop signiﬁcant myelosup-
ression. However, at the lower end of this dose range
2-4 Gy), hematologic recovery without stem cell sup-
ort might be expected. Above these limits additional
ultiorgan toxicity from acute radiation syndrome
ight limit survival. Trauma, burn or infection greatly
omplicates these assessments because animal models
nd clinical experience suggest that multiorgan injury
n addition to radiation-associated myelosuppression
reatly augments mortality and might lower the do-
imetry-based indications for stem cell support to
chieve prompt and survivable hematologic recovery.
Recommendations published by the US Strategic
ational Stockpile Working Group support the con-
ept of a limited dose range for which transplantation
hould be considered as therapeutically appropriate,
articularly when a large number of victims is involved
2,9,10]. Limited exposure yielding only a few victims
ould broaden the threshold for intensive transplan-
ation support without overtaxing available resources.
everal recent reviews have outlined management
onsiderations for radiation accidents and emphasized
his decision making in detail [2,4,9,10].
IODOSIMETRY
Clinical assessments of radiation exposure using
imply available bedside and laboratory observations
re imprecise but are generally agreed to be the most
eliable and available tools to determine who might
eed and/or beneﬁt from allogeneic HSCT in addi-
ion to other supportive care [2,7,11,12]. These bio-
osimetry tools are generally applicable to high-dose
niform exposure. Importantly, they are less applica-
le and less reliable for nonuniform radiation expo-
ure that might spare substantive areas of BM and still
e permissive of at least partial hematologic recovery
ithout transplantation. Tools to estimate biodosim-
try are available (www.affri.usuhs.mil). Time to vom-
ting from initial exposure is a generally accepted
easurement of whole body dosing. Signiﬁcant vom- Sting within 1-2 h likely implies whole body radiation
osing 4 Gy, but is neither speciﬁc to radiation nor
lways seen with high-dose exposure. The rate of
evelopment of lymphocytopenia and granulocytope-
ia is readily measurable. In the absence of research-
evel studies, evaluating chromosomal breakage and
ther techniques are not generally available. Lym-
hopenia (lymphocyte count 1000/L) within 5-7
ays or absolute neutropenia (neutrophil count
1000/L) anytime within 2 weeks implies wide-
pread marrow suppression which is expected from
4Gy. This presentation should suggest that consid-
ration and planning for HSCT might be appropriate.
ARLY EVALUATION FOR HSCT
Initial patient/radiation victim evaluation should
nclude date and time assessments of the circum-
tances of the radiation exposure, details of physical
xamination, and basic laboratory data including com-
lete blood cell count and differential. Outline of
re-existing medical conditions and comorbid burns,
rauma, or infections are important components of
atient assessment, triage, and planning for support.
artial or whole body exposure to substantive doses of
adiation includes toxicity to hematopoietic, gastroin-
estinal, and cerebrovascular systems, with particular
oxicity to rapid cell turnover in lymphopoietic, epi-
helial, and epidermal tissues [2,3,7].
UPPORTIVE CARE
First responders encounter potential radiation vic-
ims and should recognize that early initiation of ﬁl-
rastim (5-10 g/kg per day) and oral dosing with
otassium iodide (130 mg/day for adults) is indicated.
atients showing signs of 3-Gy whole body esti-
ated exposure (2 Gy for children and the elderly)
ave a need for intensive management and early ﬁl-
rastim support. Late administration of growth factors
ay be ineffective [2,4,8,13-15]. Transfusion support
ith red blood cells and platelets are indicated. Blood
roducts should be irradiated to prevent transfusion
ssociated GVHD because the extent of immunosup-
ression cannot be reliably assessed. Transfusion-as-
ociated GVHD may overlap with and resemble radi-
tion exposure because its symptomology includes
ever, rash, diarrhea, and pancytopenia. Prophylactic
ntibiotics directed toward gram-negative bacilli using
xtended-spectrum quinolones or similar agents and
uppression of yeast colonization with ﬂuconazole or
lternative agents may also be indicated as detailed in
he recommendations for management of patients with
herapy-associated neutropenia published by the Infec-
ious Diseases Society of America and the American
ociety for Blood and Marrow Transplantation [16,17].
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Radiation Emergencies 105ONOR SEARCHING
Patients whose initial biodosimetry assessments
time to vomiting and leukopenia measurements),
dentiﬁed above, and quantiﬁed using the public soft-
are available can identify patients for whom alloge-
eic HSCTmight be indicated. This also indicates the
eed for urgent donor searching. For any patients
equiring possible allogeneic transplantation, rapid
ollection of buccal swab and blood samples from the
atient and immediate siblings are indicated to deter-
ine availability of a related allogeneic donor. High-
esolution, allele-level HLA typing for HLA-A, -B,
C, and -DR loci should be performed on the poten-
ial recipient to facilitate rapid identiﬁcation of an
llogeneic unrelated volunteer or cord blood donor in
ase no family donor is identiﬁed.
NDICATIONS AND TECHNIQUES FOR HSCT
For patients with prolonged pancytopenia (no re-
overy within 21-28 days) or those whose immediate
stimated whole body exposure is4-6 Gy, allogeneic
SCT will be required to promote hematologic re-
overy and survival [2,4,8,9]. Because irradiation vic-
ims may be signiﬁcantly myelosuppressed, but inad-
quately or incompletely immunosuppressed, they
ay require additional immunosuppression to facili-
ate allogeneic hematopoietic cell engraftment, partic-
larly from unrelated or partially matched donors.
ecause marrow failure is their primary defect, the
rradiation victim’s clinical syndrome resembles trans-
lantation for aplastic anemia in the conventional
herapeutic setting. In addition, because pre-existing
adiation exposure and injury may reduce their tolerance
or intense pretransplantation conditioning, reduced in-
ensity immunosuppressive but nonmyeloablative condi-
ioning may be most appropriate. Transplantation mod-
ls for irradiation victims may therefore resemble the
idespread recent use of nonablative conditioning to
ufﬁciently immunosuppress the recipient to prevent
raft rejection without added multiorgan or epithelial
oxicity. Although low-dose total body radiation has
een widely applied for nonmyeloablative transplan-
ation, it seems intrinsically less appealing to apply to
he radiation victim. It may further compound epithe-
ial or other injury induced by the accidental radiation.
efore HSCT, highly immunosuppressive pharma-
euticals including ﬂudarabine, alemtuzumab, or
TG might be employed, perhaps accompanied by
ingle-dose cyclophosphamide, the most immunosup-
ressive of the commonly used alkylators. Similarly,
VHD prophylaxis without epithelial toxicity (avoid-
ng methotrexate) is indicated. Using cyclosporine or
acrolimus in addition to mycophenolate mofetil can
ugment immunosuppression to prevent rejection and
revent GVHD. wSupportive care through the transplantation pro-
edure should resemble conventional reduced inten-
ity transplant approaches with irradiated transfusion
upport, ﬁlgrastim to accelerate myelopoiesis, and
rophylactic and aggressive use of empiric and thera-
eutic antibiotics.
OGISTICS OF CONTINGENCY PLANNING FOR
YELOSUPPRESSION AFTER IRRADIATION
Planning for management of radiation victims is
ntimidating but essential. It forces hematologists, on-
ologists, and transplantation experts to consider the
rightening scenarios of nuclear device explosions,
ass casualties, and public health chaos, circum-
tances that are foreign to transplantation experts.
ublished model estimates of victims suggest that a
-kiloton improvised nuclear device in major city
ould expose up to 33 000 patients to 3-5 Gy of
adiation requiring critical support and 19 000 more
o 5-8 Gy, likely requiring transplantation [2,4,8].
hese demands are well beyond any possible capacity
o even contemplate urgent and intensive hematologic
nd transplantation care with the necessities of anti-
iotics, blood products, transplantation beds, and
ransplantation physician expertise. Greater exposure
a 10-kiloton explosive) would markedly increase the
umber of traumatic injuries and increase the number
f victims with life-threatening hematologic toxicity
y 3- to 5-fold. Limited victim radiation accidents and
ndustrial or contained military or terrorist exposure
ould yield only a few or even hundreds of patients
equiring support and care at centers remote from the
ite of initial injury and radiation exposure where the
edical infrastructure is undamaged. Effective man-
gement of patients, even after transport, cannot take
lace without contingency planning, preparedness,
nd pre-established therapeutic protocols for evalua-
ion, management, and treatment.
Additional elements required for effective pre-
aredness are prospective data collection to learn from
ach experience and to improve processes and tech-
iques for the next events. Satisfactory contingency
rotocols, resembling prospective phase II trials, must
e reviewed and established across a preparedness
etwork to allow prompt activation and treatment.
imilarly, their review and acceptance by donor and
ord blood networks to provide unrelated hematopoi-
tic cell donors for those in need must be preplanned
nd designed for urgent activation and action.
UMMARY
Foresight, planning, and education are not always
ufﬁcient to manage medical urgencies, particularly
hen facing frightening and uncertain experience or
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D. Weisdorf et al.106oo many urgent victims. The challenge to the hema-
ology, oncology, and transplantation community is
o think ahead, to plan, and be prepared. Developed
xpertise to support elective transplantation for cancer
ould be life-saving for radiation accident victims of
he future. Contingency planning will help us manage
his challenge, even while we hope it never occurs.
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